Outlook Therapeutics, Inc.
OTLK evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $151.2M
- Lead Asset:
- ons-5010/lytenava (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for OTLK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OTLK
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg) for retinal diseases, with FDA approval and a planned U.S. commercial launch before year-end 2026.
Key risk: Negative equity and net loss
BioSniper Score
Based on 4 of 6 signals
Market Cap
$151.2M
Cash Runway
—
Lead Asset
ons-5010/lytenava (BLA Filed)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials · 1 FDA decision for Outlook Therapeutics, Inc..
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg) for retinal diseases, with FDA approval and a planned U.S. commercial launch before year-end 2026.
- Outlook Therapeutics is focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases [news · published 2026-08-06].
- LYTENAVA is described as the only FDA-approved ophthalmic bevacizumab, addressing a significant need in the U.S. wet AMD market [news · published 2026-08-14].
- The company reported cash & equivalents of $11.2M as of 2026-06-30 [sec].
- Outlook Therapeutics submitted an HCPCS Level II application to CMS for a permanent J-code for LYTENAVA and remains on track for a U.S. commercial launch before year-end 2026 [news · published 2026-10-01].
- The company completed a $55.0 million underwritten public offering of common stock and warrants in August 2026 [news · published 2026-08-13].
What works
- LYTENAVA is the only FDA-approved ophthalmic bevacizumab, which may provide a competitive advantage in the wet AMD market where bevacizumab is already widely used [news · published 2026-08-14].
- The company has an ongoing U.S. launch strategy including reimbursement, pricing, and supply capabilities, and has submitted a J-code application to CMS [news · published 2026-08-14][news · published 2026-10-01].
- Outlook Therapeutics has established a commercial distribution agreement in Europe (Switzerland) and launched a real-world evidence study in Germany [news · published 2026-05-15].
What to weigh
- The company reported a net loss of -$20.3M and negative shareholders' equity of -$10.4M as of 2026-06-30 [sec].
- Cash & equivalents were $11.2M as of 2026-06-30, which may be limited relative to the costs of a commercial launch [sec].
- The company had to complete a Formal Dispute Resolution Meeting with the FDA regarding a Complete Response Letter (CRL) for ONS-5010, indicating prior regulatory hurdles [news · published 2026-05-15].
- Outlook Therapeutics has not yet reported product revenue from LYTENAVA, and its commercial success is unproven [sec].
From the filings
Quoted directly from source documents.
LYTENAVA is the only FDA-approved ophthalmic bevacizumab.
“The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used”
News · August 14, 2026
Company completed a $55.0 million public offering in August 2026.
“Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants”
News · August 13, 2026
Company submitted HCPCS Level II application to CMS for a permanent J-code.
“Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)”
News · October 1, 2026
Catalyst timeline
- 2019-06-25 · Phase3_Start: A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration — Initiation of a Phase 3 efficacy and safety study of ONS-5010 in wet AMD.
- 2020-10-01 · Phase3_Start: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE — Initiation of a Phase 3 safety study of ONS-5010 in retinal disorders.
- 2021-11-15 · Phase3_Start: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN — Initiation of a Phase 3 safety study comparing vial and prefilled syringe formulations.
- 2024-01-24 · Phase3_Start: Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration — Initiation of a Phase 3 study comparing ONS-5010 to Lucentis in wet AMD.
Risks & what to watch (4)›
Key risks
- Negative equity and net loss — Shareholders' equity was -$10.4M and net income was -$20.3M as of 2026-06-30 [sec].
- Limited cash for launch — Cash & equivalents of $11.2M as of 2026-06-30 may be insufficient to fund a full commercial launch without additional financing [sec].
- Unproven commercial revenue — The company has not yet reported product revenue from LYTENAVA; commercial success is unproven [sec].
- Prior FDA regulatory setback — Company had to complete a Formal Dispute Resolution Meeting with FDA regarding a CRL for ONS-5010 [news · published 2026-05-15].
What to watch
- U.S. commercial launch of LYTENAVA before year-end 2026 [news · published 2026-10-01].
- CMS decision on the permanent J-code application for LYTENAVA [news · published 2026-10-01].
- Next quarterly financial results and any updates on product revenue [news · published 2026-08-06].
- Progress of the real-world evidence study in Germany and European commercial expansion [news · published 2026-05-15].
Sources: Catalysts · News · Pipeline · Generated October 14, 2026 · How we verify sources →
Run Outlook Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Outlook Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$20M
Lead: BLA Filed
1 candidate
No upcoming catalysts tracked
10 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$2.2M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 4,168,000 | $858K |
| vanguard capital management llc | 1,967,160 | $405K |
| geode capital management, llc | 603,606 | $124K |
| gilpin wealth management, llc | 600,162 | $124K |
| blackrock, inc. | 477,471 | $98K |
| commonwealth equity services, llc | 470,000 | $97K |
| warberg asset management llc | 275,000 | $56K |
| renaissance technologies llc | 255,157 | $53K |
| nine masts capital ltd | 232,546 | $48K |
| connective capital management, llc | 200,000 | $41K |
Showing top 10 of 54 institutional holders of Outlook Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 5.3%
- Days to cover
- 1.3
- Shares short
- 6,433,813
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OTLK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Outlook Therapeutics, Inc.?
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg) for retinal diseases, with FDA approval and a planned U.S. commercial launch before year-end 2026.
What is Outlook Therapeutics, Inc.'s lead drug candidate?
Outlook Therapeutics, Inc.'s most advanced tracked candidate is ons-5010/lytenava (BLA Filed) for wet age-related macular degeneration (wet AMD).
Who is the CEO of Outlook Therapeutics, Inc.?
Mr. Robert Charles Jahr is the chief executive officer of Outlook Therapeutics, Inc. (OTLK).
Where is Outlook Therapeutics, Inc. headquartered?
Outlook Therapeutics, Inc. (OTLK) is headquartered in Iselin, NJ, United States.
What therapeutic areas does Outlook Therapeutics, Inc. focus on?
Outlook Therapeutics, Inc. develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.